title: Clinical experience with the right gastroepiploic artery in coronary artery bypass grafting.
abstract: The excellent long-term results with the internal mammary artery for coronary artery bypass grafting have prompted the search for other conduits with similar characteristics. From December 1989 to December 1991, the right gastroepiploic artery (RGEA) has been used as an in situ graft to the posterior descending coronary artery in 51 patients at the Montreal Heart Institute. The patients' age averaged 50 +/- 11 years. Three-vessel coronary artery disease was present in 41 patients and two-vessel disease in the remaining 10 patients. In all but 1 patient, bilateral internal mammary artery grafting was performed in addition to RGEA grafting. The number of grafts per patient averaged 3.2 +/- 0.8. There was no operative mortality. Morbidity was minimal with only myocardial infarction and a pleural effusion in 1 patient. In 1 patient, a splenectomy had to be performed because of iatrogenic tear during dissection of the RGEA. The average hospital stay was 8.2 +/- 2.6 days. Enteral nutrition was resumed on average 2 days after operation. Angiographic evaluation of RGEA grafts was performed before discharge or within the first month after surgery in 31 patients. In 28 patients (28/31, 90%) the RGEA graft was patent, two grafts were occluded, and in the remaining patient, the graft could not be visualized due to technical difficulties during angiography. A second angiographic evaluation was performed in 5 patients, 1 year after operation. Four RGEAs were patent and 1 was occluded. Clinical follow-up averaged 4 months (range 1 to 15 months).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, Montreal Heart Institute, Quebec, Canada.
authors.forename: L P
authors.initials: LP
authors.lastname: Perrault
authors.forename: M
authors.initials: M
authors.lastname: Carrier
authors.forename: Y
authors.initials: Y
authors.lastname: Hébert
authors.forename: G
authors.initials: G
authors.lastname: Hudon
authors.forename: R
authors.initials: R
authors.lastname: Cartier
authors.forename: Y
authors.initials: Y
authors.lastname: Leclerc
authors.forename: L C
authors.initials: LC
authors.lastname: Pelletier
mesh_terms: D000328:Adult; D001158:Arteries / Q000637:transplantation; D002316:Cardiotonic Agents / Q000627:therapeutic use; D001026:Coronary Artery Bypass / Q000379:methods*; D003327:Coronary Disease / Q000097:blood / Q000000981:diagnostic imaging / Q000601:surgery*; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008323:Mammary Arteries / Q000637:transplantation; D008875:Middle Aged; D009852:Omentum / Q000098:blood supply*; D011182:Postoperative Care; D011183:Postoperative Complications; D011859:Radiography; D013270:Stomach / Q000098:blood supply*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002316:Cardiotonic Agents; D007527:Isoenzymes; D003402:Creatine Kinase